Reuters
Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set
to reach the market in 2015, among 11 products each with $1 billion-plus sales
potential, according to a Thomson Reuters analysis.
More potential blockbusters are expected to be launched this year than
last, in an encouraging sign for the pharmaceutical industry, which relies on
new products to replenish sales as older medicines go off patent.
Regulators have been approving more new drugs in recent years but there
remains a debate as to how far this will translate into bigger overall sales
and profits, since many modern medicines are for rare diseases.
The three biggest potential blockbusters launching this year, however,
offer new ways of fighting cancer, high cholesterol and heart failure -- all
markets targeting relatively large numbers of patients.
In total, 11 of the many new drugs set for launch in 2015 are expected to
generate $1 billion-plus annual sales within five years, up from three in 2014,
Thomson Reuters Cortellis said in its latest "Drugs to Watch" report
on Monday.
Bristol-Myers' cancer medicine Opdivo tops the list, with projected 2019
sales of $5.7 billion, according to consensus forecasts compiled by Cortellis.
Opdivo belongs to a new class of medicines called PD-1 inhibitors that work
by blocking a mechanism tumours use to hide from the immune system, allowing it
to recognise and attack cancer cells.
The drug went on sale in Japan in September 2014 but was only approved for melanoma in the United States
at the end of December, since when it has also received a green light for lung
cancer, underlying the potential that healthcare authorities see in such
so-called immunotherapies.
Sanofi's cholesterol drug Praluent, which is being developed with Regeneron
Pharmaceuticals, is expected to generate annual sales in 2019 of $4.4 billion
-- twice that seen for Amgen's rival Repatha.
The U.S. Food and Drug Administration is due to decide this summer whether
to approve the two drugs, which both tackle difficult-to-treat cases of high
cholesterol by targeting a protein known as PCSK9.
Novartis' new first-in-class heart failure drug LCZ-696, meanwhile, is
forecast to sell $3.7 billion by 2019, following impressive clinical trial
results. The drug
could win U.S. approval in August.
Φαρμακευτικό Μάρκετινγκ: Θεωρία, Πρακτική, Δεοντολογία
Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…
Φαρμακευτικό Μάρκετινγκ: Θεωρία, Πρακτική, Δεοντολογία
The
ultimate guide for Pharma Marketing Champions
Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…